Induction of Autoimmunity by Adjuvant Hydrocarbons

Infection and Autoimmunity, 2nd edition

Volumn , Issue , 2004, Pages 87-104

  Kelly, Kindra M ^a   Kuroda, Yoshiki ^a   Nacionales, Dina C ^a   Akaogi, Jun ^a   Satoh, Minoru ^a   Reeves, Westley H ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54549126259     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044451271-0.50008-9     Document Type: Chapter

References (138)

1. Morel L, Mohan C, Yu Y, Croker BP, Tian N, Deng A, et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol 1997, 158(12):6019-6028.
2. Satoh M, Reeves WH Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 1994, 180:2341-2346.
3. Satoh M, Kumar A, Kanwar YS, Reeves WH Antinuclear antibody production and immune complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA 1995, 92:10934-10938.
4. Wooley PH, Seibold JR, Whalen JD, Chapdelaine JM Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease. Arthritis Rheum 1989, 32:1022-1030.
5. Satoh M, Richards HB, Shaheen VM, Yoshida H, Shaw M, Naim JO, et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol 2000, 121:399-405.
6. Satoh M, Kuroda Y, Yoshida H, Behney KM, Mizutani A, Akaogi J, et al. Induction of lupus autoantibodies by adjuvants. J Autoimm 2003, 21:1-9.
7. Ramon G Sur la toxine et sur l'anatoxine diphtheriques. Ann Inst Pasteur 1924, 38:1-10.
8. Spickard A Exogenous lipoid pneumonia. Arch Intern Med 1994, 154:686-692.
9. Wanless IR, Geddie WR Mineral oil lipogranulomata in liver and spleen: a study of 465 autopsies. Arch Pathol Lab Med 1985, 109:283-286.
10. Gwynne-Jones DP Accidental self inoculation with oil based veterinary vaccines. NZ Med J 1996, 109:363-365.
11. Gupta RK, Relyveld EB, Bizzini B, Ben-Efraim S, Gupta CK Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 1993, 11:293-306.
12. Audibert FM, Lise LD Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993, 14:281-284.
13. Kohashi O, Tanaka S, Kotani S, Shiba T, Kusumoto S, Yokogawa K, et al. Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition. Infect Immun 1980, 29:70-75.
14. Potter M, Boyce CR Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature (Lond) 1962, 193:1086-1087.
15. Beebe GW, Simin AH, Vivona S Long-term mortality follow-up of army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 1972, 95:337-346.
16. Shaw CM, Alvord EC, Kies MW Straight chain hydrocarbons as substitutes for the oil in Freund's adjuvants in the production of experimental "allergic" encephalomyelitis in guinea pig. J Immunol 1964, 92:24-27.
17. Whitehouse MW, Orr KJ, Beck FWJ, Pearson CM Freund's adjuvants: relationship of arthritogenicity and adjuvanticity in rats to vehicle composition. Immunol 1974, 27:311-330.
18. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994, 180:1243-1250.
19. Crowle AJ, Hu CC A comparison on n-hexadecane and mineral oil emulsions in induction of hypersensitivity in mice. Proc Soc Exp Biol Med 1966, 123:94-97.
20. Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, McDonald DM, et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 2001, 31(10):2910-2918.
21. Herbert WJ The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunol 1968, 14(3):301-318.
22. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, Van Nest G, Ott G, et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998, 186(1):18-27.
23. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (Lond) 1995, 374:546-549.
24. Krieg AM CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
25. Banchereau J, Steinman RM Dendritic cells and the control of immunity. Nature (Lond) 1998, 392:245-252.
26. Palucka K, Banchereau J Linking innate and adaptive immunity. Nat Med 1999, 5(8):868-870.
27. Cyster JG Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 1999, 189(3):447-450.
28. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998, 188(11):2163-2173.
29. Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, Germain RN, et al. In vivo microbial stimulation induces rapid CD40 ligand- independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med 1997, 186(11):18189.
30. Steinman RM, Turley S, Mellman I, Inaba K The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000, 191(3):411-416.
31. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194(6):769-779.
32. Matzinger P Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045.
33. Kaisho T, Akira S Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589(1):1-13.
34. Akira S, Yamamoto M, Takeda K Role of adapters in Toll-like receptor signalling. Biochem Soc Trans 2003, 31(Pt 3):637-642.
35. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001, 167(10):5887-5894.
36. Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P, Wu T, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002, 17(3):251-263.
37. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3(2):196-200.
38. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14(4):461-470.
39. Sen GC, Lengyel P The interferon system. J Biol Chem 1992, 267(8):5017-5020.
40. Diaz MO, Pomykala HM, Bohlander SK, Maltepe E, Malik K, Brownstein B, et al. Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics 1994, 22(3):540-552.
41. Taniguchi T, Takaoka A A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001, 2(5):378-386.
42. Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BR, Li X Poly(dI×dC)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem 2003, 278(19):16713-16719.
43. Brierley MM, Fish EN Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. J Interferon Cytokine Res 2002, 22(8):835-845.
44. Kadowaki N, Antonenko S, Lau JY, Liu YJ Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000, 192(2):219-226.
45. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3(9):822-829.
46. Marrack P, Kappler J, Mitchell T Type I interferons keep activated T cells alive. J Exp Med 1999, 189(3):521-529.
47. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 2001, 97(6):1555-1559.
48. Su L, David M Inhibition of B cell receptor-mediated apoptosis by IFN. J Immunol 1999, 162:6317-6321.
49. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19(2):225-234.
50. Finkelman FD, Svetic A, Gresser I, Snapper C, Holmes J, Trotta PP, et al. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991, 174(5):1179-1188.
51. Sun S, Zhang X, Tough DF, Sprent J Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998, 188(12):2335-2342.
52. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31(7):2154-2163.
53. Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH IL-6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 1998, 188:985-990.
54. Satoh M, Hamilton KJ, Ajmani AK, Dong X, Wang J, Kanwar YS, et al. Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane. J Immunol 1996, 157:3200-3206.
55. Satoh M, Shaheen VM, Kao PN, Okano T, Shaw M, Yoshida H, et al. Autoantibodies define a family of proteins with conserved double-stranded RNA binding domains as well as DNA-binding activity. J Biol Chem 1999, 274:34598-34604.
56. Yang JQ, Singh AK, Wilson MT, Satoh M, Stanic AK, Park JJ, et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol 2003, 171(4):2142-2153.
57. Satoh M, Weintraub JP, Yoshida H, Shaheen VM, Richards HB, Shaw M, et al. Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus. J Immunol 2000, 165:1036-1043.
58. Richards HB, Satoh M, Jennette JC, Okano T, Kanwar YS, Reeves WH Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. Clin Exp Immunol 1999, 115:547-553.
59. Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatsuki F, et al. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 1987, 84:228-231.
60. Taga T, Kawanishi Y, Hardy RR, Hirano T, Kishimoto T Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J Exp Med 1987, 166:967-981.
61. Nordan RP, Potter M A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science (Wash, DC) 1986, 233:566-569.
62. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995, 182:243-248.
63. Dedera DA, Urashima M, Chauhan D, LeBrun DP, Bronson RT, Anderson KC Interleukin-6 is required for pristane-induced plasma cell hyperplasia in mice. Br J Hematol 1996, 94:53-61.
64. Nagafuchi H, Suzuki N, Mizushima Y, Sakane T Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol 1993, 151:6525-6534.
65. Kobayashi I, Matsuda T, Saito T, Yasukawa K, Kikutani H, Hirano T, et al. Abnormal distribution of IL-6 receptor in aged MRL/lpr mice: elevated expression on B cells and absence on CD4+ cells. Int Immunol 1992, 4:1407-1412.
66. Tang B, Matsuda T, Akira S, Nagata N, Ikehara S, Hirano T, et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol 1991, 3:273-278.
67. Jourdan M, Bataille R, Seguin J, Zhang XG, Chaptal PA, Klein B Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum 1990, 33:398-402.
68. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989, 74:1360-1367.
69. Trinchieri G Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3(2):133-146.
70. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, Heeger PS, et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichtomy defines the class of response. J Immunol 1999, 162:3942-3949.
71. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997, 186:1623-1631.
72. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001, 31(10):3026-3037.
73. Satoh M, Treadwell EL, Reeves WH Pristane induces high titers of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice. Quantitation by antigen capture ELISAs based on monospecific human autoimmune sera. J Immunol Methods 1995, 182:51-62.
74. Snapper CM, Perchel C, Paul WE IFN-gamma stimulated IgG2a secretion by murine B cells stimulated with lipopolysaccharide. J Immunol 1988, 140:2121-2127.
75. Richards HB, Satoh M, Jennette JC, Croker BP, Reeves WH Interferon-gamma promotes lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 2001, 60:2173-2180.
76. Calvani N, Satoh M, Croker BP, Reeves WH, Richards HB Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. Kidney Int 2003, 64:897-905.
77. Hamilton KJ, Satoh M, Swartz J, Richards HB, Reeves WH Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. Clin Immunol Immunopathol 1998, 86:271-279.
78. Naim JO, Satoh M, Buehner NA, Ippolito KM, Yoshida H, Nusz D, et al. Induction of hypergammaglobulinemia and macrophage activation by silicone gels and oils in female A.SW mice. Clin Diagn Lab Immunol 2000, 7(3):366-370.
79. Ravetch JV, Bolland S IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290.
80. Clynes R, Dumitru C, Ravetch JV Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science (Wash, DC) 1998, 279(5353):1052-1054.
81. Fries JWU, Mendrick DL, Rennke HG Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988, 34:333-345.
82. Couser WG Pathogenesis of glomerulonephritis. Kidney Int 1993, 44(Suppl. 42):19-26.
83. Horii Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, et al. Inovlvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol 1989, 143:3949-3955.
84. Ruef C, Budde K, Lacy J, Northemann W, Baumann M, Sterzel RB, et al. Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int 1990, 38:249-257.
85. Kiberd BA Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 1993, 4:58-61.
86. Haas C, Le Hir M IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J Immunol 1997, 158:5484-5491.
87. lpr mice. J Immunol 1998, 161:494-503.
88. Naito T, Yokoyama H, Moore KJ, Dranoff G, Mulligan RC, Kelley VR Macrophage growth factors introduced into the kidney initiate renal injury. Mol Med 1996, 2(3):297-312.
89. Potter M, Wax JS Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: Reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol 1981, 127:1591-1595.
90. Raj NB, Cheung SC, Rosztoczy I, Pitha PM Mouse genotype affects inducible expression of cytokine genes. J Immunol 1992, 148:1934-1940.
91. Feldmann M, Brennan FM, Maini RN Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
92. Beech JT, Thompson SJ Anti-tumour necrosis factor therapy ameliorates joint disease in a chronic model of inflammatory arthritis. Br J Rheumatol 1997, 36(10):1129.
93. Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000, 156(6):2057-2065.
94. Cohen PL, Eisenberg RA Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991, 9:243-269.
95. Russell JH, Rush B, Weaver C, Wang R Mature T cells of autoimmune lpr/lpr mice have a defect in antigenstimulated suicide. Proc Natl Acad Sci USA 1993, 90:4409-4413.
96. + T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells. J Immunol 1998, 161:3292-3298.
97. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999, 190(6):815-826.
98. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998, 19(1):56-59.
99. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-presented antigens to cytotoxic T lymphocytes. J Exp Med 1998, 188(7):1359-1368.
100. Fadok VA, Bratton DL, Henson PM Phagocytes receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 2001, 108(7):957-962.
101. Satoh M, Mizutani A, Behney KM, Kuroda Y, Akaogi J, Yoshida H, et al. X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus. Int Immunol 2003, 15(9):1117-1124.
102. Takeda Y, Caudell P, Grady G, Wang G, Suwa A, Sharp GC, et al. Human RNA helicase A is a lupus autoantigen that is cleaved during apoptosis. J Immunol 1999, 163(11):6269-6274.
103. Yoshida H, Satoh M, Behney KM, Lee CG, Richards HB, Shaheen VM, et al. Effect of an exogeneous trigger on the pathogenesis of lupus in NZB X NZW (F1) mice. Arthritis Rheum 2002, 46:2235-2244.
104. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. Nature (Lond) 1994, 372(6507):691-694.
105. Bly JE, Garrett LR, Cuchens MA Pristane induced changes in rat lymphocyte membrane fluidity. Cancer Biochem Biophys 1990, 11:145-154.
106. Janz S, Shacter E A new method for delivering alkanes to mammalian cells: preparation and preliminary characterization of an inclusion complex between β-cyclodextrin and pristane (2,6,10,14-tetramethylpentadecane). Toxicology 1991, 69:301-315.
107. Gawrisch K, Janz S The uptake of pristane (2,6,10,14-tetramethylpentadecane) into phospholipid bilayers as assessed by NMR, DSC, and tritium labeling methods. Biochim Biophys Acta 1991, 1070(2):409-418.
108. kalergis AM, Lopez CB, Becker MI, Diaz MI, Sein J, Garbarino JA, et al. Modulation of fatty acid oxidation alters contact hypersensitivity to urushiols: role of aliphatic chain beta-oxidation in processing and activation of urushiols. J Invest Dermatol 1997, 108(1):57-61.
109. Kalish RS, Wood JA Induction of hapten-specific tolerance of human CD8+ urushiol (poison ivy)-reactive T lymphocytes. J Invest Dermatol 1997, 108(3):253-257.
110. Hardy RR, Hayakawa K B cell development pathways. Annu Rev Immunol 2001, 19:595-621.
111. Richards HB, Reap EA, Shaw M, Satoh M, Yoshida H, Reeves WH B cell subsets in pristane-induced autoimmunity. Curr Top Microbiol Immunol 2000, 252:201-207.
112. Leak LV, Potter M, Mayfield WJ Response of the peritoneal mesothelium to the mineral oil, pristane. Curr Top Microbiol Immunol 1985, 122:221-233.
113. Anderson AO, Wax JS, Potter M Differences in the peritoneal response to pristane in BALB/cAnPt and BALB/cJ mice. Curr Top Microbiol Immunol 1985, 122:242-253.
114. Potter M, MacCardle RC Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice. J Natl Cancer Inst 1964, 33:497-515.
115. Garosi G, Di Paolo N Recent advances in peritoneal morphology: the milky spots in peritoneal dialysis. Adv Perit Dial 2001, 17:25-28.
116. Hjelmstrom P Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukoc Biol 2001, 69(3):331-339.
117. Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. J Clin Invest 1998, 102(5):938-946.
118. Xanthou G, Polihronis M, Tzioufas AG, Paikos S, Sideras P, Moutsopoulos HM "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: Possible participation in lymphoid structure formation. Arthritis Rheum 2001, 44(2):408-418.
119. Schroder AE, Greiner A, Seyfert C, Berek C Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996, 93:221-225.
120. Randen I, Mellbye OJ, Forre O, Natvig JB The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue. Scand J Immunol 1995, 41(5):481-486.
121. Singh B, Rabinovitch A Influence of microbial agents on the development and prevention of autoimmune diabetes. Autoimmunity 1993, 15:209-213.
122. Adams RB, Planchon SM, Roche JK IFN-gamma modulation of epithelial barrier function: time course, reversibility, and site of cytokine binding. J Immunol 1993, 150:2356-2363.
123. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J Induction of Dendritic Cell Differentiation by IFN-alpha in Systemic Lupus Erythematosus. Science (Wash, DC) 2001, 294(5546):1540-1543.
124. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991, 147(1):117-123.
125. Malide D, Russo P, Bendayan M Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995, 26:558-564.
126. Martin M, Schwinzer R, Schellekens H, Resch K Glomerular mesangial cells in local inflammation: induction of the expression of MHC calls II antigens by IFN-gamma. J Immunol 1989, 142(6):1887-1894.
127. Nanki T, Tomiyama J, Arai S Mixed connective tissue disease associated with multicentric Castleman's disease. Scand J Rheumatol 1994, 23:215-217.
128. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 1991, 18(10):1621-1622.
129. Fiorani C, Sacchi S, Bonacorsi G, Cosenza M Systemic sarcoidosis associated with interferon-alpha treatment for chronic myelogenous leukemia. Haematologica 2000, 85(9):1006-1007.
130. Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999, 53(5-6):242-254.
131. Ioannou Y, Isenberg DA Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000, 43:1431-1442.
132. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K Antibodies against doublestranded DNA and development of polymyositis during treatment with interferon. Q J Med 1998, 91(6):393-399.
133. Ronnblom LE, Alm GV, Oberg KE Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors (see comments). Ann Intern Med 1991, 115(3):178-183.
134. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987, 70(3):562-569.
135. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979, 301(1):5-8.
136. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science (Wash, DC) 1982, 216(4544):429-431.
137. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615.
138. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197(6):711-723.